Leveraging Fermentation Heat Transfer Data to Better Understand Metabolic Activity - - BioPharm International

ADVERTISEMENT

Leveraging Fermentation Heat Transfer Data to Better Understand Metabolic Activity


BioPharm International
Volume 21, Issue 4

RESULTS, DISCUSSION, AND CONCLUSION


Figure 3. The oxygen uptake rate (OUR) calculated from the heat removal data as compared to the measured OUR
As shown in the comparative OUR plot (Figure 3), the values calculated from the heat removal information follow the data gathered using a mass spectrometer. They may not exactly match, but they are close enough from a comparative standpoint. The heat-generated OUR data allow a researcher to understand the metabolic state of a process, and show what the peak OUR values are likely to be. The data can be further defined using more exacting flow measurements and coolant flow control. For the above example, much of the noise that enters the heat removal data pool stems from the flow fluctuations that result from the pulses of coolant into the recirculating fluid in the jacket or coils of the fermenter. The secondary value of such heat removal OUR data lay with the corroboration of other OUR calculation methodologies. If a mass spectrometer is normally used to calculate OUR values, the data can be verified by the heat removal for the fermenter. The heat removal information adds an important data set for scale-up purposes.

Mark Berge is a scientist, Swapnil Bhargava is a senior scientist, Radu Georgescu is an associate scientist, and Xiaoming (Jerry) Yang is scientific director, all at Amgen, Inc., Thousand Oaks, CA, 805.313.6362,

REFERENCES

1. Cooney CL, Wang DIC, Mateles RI. Measurement of heat evolution and correlation with oxygen consumption during microbial growth. Biotechnol Bioeng. 2000 Mar 20;67(6):691–703.

2. Bailey J, Ollis D. Biochemical engineering fundamentals. New York: McGraw-Hill; 1986.

3. Lydersen B, D'elia N, Nelson K. Bioprocess engineering: systems, equipment, and facilities. Hoboken, NJ: John Wiley & Sons Inc.; 1994.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

FDA Panel Unanimously Backs Secukinumab for the Treatment of Psoriasis
October 22, 2014
Roche to Expand and Improve its Basel Site
October 22, 2014
Pall ForteBio Releases Bioprocessing Contamination Detection Kit
October 22, 2014
EMA Works to Speed Up Ebola Treatment
October 20, 2014
Amgen Sues Sanofi and Regeneron over Patent for mAb Targeting PCSK9
October 20, 2014
Author Guidelines
Source: BioPharm International,
Click here